Paraguay Device Families, Systems and Kits: Grouping Rules under Articles 20 and 21
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
- Article 21 allows registration applications to be submitted for families (familias), systems (sistemas) and Kits of devices, with the grouping to be made according to the definitions in the resolution. Grouping is therefore a defined regulatory construct, not a commercial convenience that can be arranged freely.
- The key rule: the procedure is determined by the product with the highest risk class within the family, system or Kit. One high-class component pulls the entire grouping into the corresponding procedure, together with its review depth and timeframe.
- Article 20 provides that combination devices (dispositivos médicos combinados) are evaluated according to the scientific and technical approach of the regulatory authority of the reference country, although the applicant may still be asked to supplement new technical and administrative requirements.
- Item 20 of the definitions chapter of the resolution defines kits/sets as collections of devices that could be registered individually but are combined into a single sales unit for a specific use or specific operation.
2. Legal basis
| Regulation | Reference | Date | Provisions |
|---|---|---|---|
| Resolution on market authorization requirements for medical devices | Resolución DINAVISA N° 226/2024 | 2024-08-27; Article 36: entered into force 2024-09-16 | Articles 20 and 21; item 20 of the definitions chapter |
| Operational instructions and guide for submitting applications | Instructivo ITR–DGRS-002, Versión 02 | 2024-09-09 | Page 4, Denominación Comercial / Modelo / Detalles de Accesorio |
The substantive rules on grouping sit in the resolution, while the operational instructions, at page 4, govern how the grouping is expressed on the platform: the commercial name, the model and the accessory details are declared in structured fields, and accessories carry their own reference code, identifying name and specifications. Because the platform fields are what reviewers and inspectors see first, the grouping declared there must match the definitions used in the resolution; a family declared as a kit, or accessories omitted from the accessory details, creates a mismatch that surfaces later as a finding.
The grouping decision also reaches forward into the post-market phase. Every certificate issued for a family, system or kit carries the grouping inside its scope, so a change to any component under the Article 13 classification is evaluated against the whole grouping, not against the component alone. Removing a component, adding a model or altering a shared accessory can shift the highest class, and if the change moves the grouping into a higher class, the existing certificate no longer describes the product as sold. For that reason, the component list, the class of each component and the grouping rationale should be kept as living documents in the regulatory file, updated whenever the portfolio changes, so that the original grouping logic remains verifiable years after the certificate was issued.
3. Expert insights
Insight one: filing by family is an efficiency tool, but the price is the highest class governs. Article 21 allows consolidated applications for families, which significantly reduces the number of certificates and the workload of subsequent changes; but if a single Class III component enters the grouping, the whole family proceeds through the Class III procedure. Whether to group is in substance a trade-off between the number of certificates and their maintenance cost on one side, and the depth and duration of a single review on the other. The right answer differs by portfolio: consumable-heavy portfolios group aggressively, while portfolios with one high-class item often isolate that item in its own application.
Insight two: the treatment of combination devices shows that Paraguay recognizes cross-boundary products. Article 20 does not set its own rules for determining combination status; it refers to the scientific and technical approach of the reference authority, such as whether the drug or the device provides the principal intended action. This means that the classification and the principal mode of action determination for a combination device depend heavily on the existing regulatory conclusion of the country of origin, and manufacturers from China and other origins should prepare documentation from the original approval authority expressing its position on the principal mode of action. DINAVISA may still request supplementary technical and administrative requirements, so the foreign conclusion frames the review but does not close it.
Insight three: declaring accessories and filing by family are two different matters. The operational instructions require the accessories of a device to be declared individually, including reference code, identifying name and specifications, and to be indicated in the CLV or technical documentation. Accessories may be declared together with the main device, but the grouping rules for kits/sets differ: the former is a main device plus accessories, while the latter is a sales unit composed of multiple devices that could each be registered independently. Confusing the two constructs leads to the wrong declaration structure on the platform and, downstream, to the wrong change classification.
4. Practical recommendations
- Before deciding on a family application, list every component in the family with its class, and confirm whether the procedure and timeframe corresponding to the highest class are acceptable; the exercise takes little time and prevents the most expensive grouping mistakes.
- For combination device projects, prepare in advance the written conclusion of the original approval authority on the principal mode of action (PMOA), translated and ready to be submitted as part of the technical documentation.
- Keep the accessory list in one-to-one correspondence with the CLV and technical documentation, and mark on the relevant document pages, by highlighting or explicit reference, the corresponding accessories and models so the reviewer can trace each accessory without interpretation.
- Handle subsequent changes to a family under the classification of Article 13; changes affecting the composition or function of the family generally fall into Class II changes, which require approval before implementation.
5. Verification checklist
- □ All components of the family listed together with their classes before the grouping decision
- □ Procedure confirmed to follow the highest class in the grouping
- □ Principal mode of action conclusion document obtained from the original approval authority for combination devices
- □ Accessory list mapped one-to-one to the CLV and technical documentation with markings applied
- □ Changes within the family pre-classified under Article 13 before implementation
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support for manufacturers, importers and authorized representatives in Paraguay, covering grouping strategy, combination device documentation and change classification under Articles 20 and 21 of Resolución DINAVISA N° 226/2024. Contact: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us